產(chǎn)品詳情
簡(jiǎn)單介紹：
Anti-RCAS1/EBAG9抗體產(chǎn)品質(zhì)量穩(wěn)定，實(shí)驗(yàn)效果明顯，貨期快，價(jià)格優(yōu)惠，歡迎垂詢訂購(gòu)！我公司長(zhǎng)期供應(yīng)**組化抗體、WB抗體、**組化試劑盒和抗體試驗(yàn)所需全部相關(guān)試劑、熒光標(biāo)記抗體、單克隆抗體、多克隆抗體、各種標(biāo)記的二抗IgG/IgM/IgD/IgA等科研實(shí)驗(yàn)抗體。Anti-RCAS1/EBAG9抗體用于**組化實(shí)驗(yàn),WB實(shí)驗(yàn),相應(yīng)的標(biāo)記抗體有HRP標(biāo)記抗體,FITC標(biāo)記,BIO等。
詳情介紹：
Rabbit Anti-RCAS1/EBAG9
Cat. Number:
Anti-RCAS1/EBAG9抗體KL-6809R
Quantity size:
0.2ml
Concentration:
1mg/ml Buffer = 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Background:
This gene was identified as an estrogen-responsive gene. Regulation of transcription by estrogen is mediated by estrogen receptor, which binds to the estrogen-responsive element found in the 5'-flanking region of this gene. The encoded protein is a tumor-associated antigen that is expressed at high frequency in a variety of Anti-RCAS1/EBAG9抗體cancers. Alternate splicing results in multiple transcript variants. A pseudogene of this gene has been defined on chromosome 10. [provided by RefSeq, Jul 2013]
Also known as:
BAG9; Cancer associated surface antigen; Cancer associated surface antigen RCAS1; EB9; EBAG 9; Estrogen receptor binding fragment associated gene 9 protein; Estrogen receptor binding site associated antigen 9; PDAF; RCAS 1; Anti-RCAS1/EBAG9抗體RCAS1; Receptor binding cancer antigen expressed on SiSo cells.
Specificity:
●
Rabbit Polyclonal IgG, affinity purified by Protein A.
●
Reacts with: Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Rabbit, .
●
Immunogen: KLH conjugated synthetic Anti-RCAS1/EBAG9抗體peptide derived from human EBAG9/RCAS1.
●
Predicted Molecular Weight: 24kDa.
Storage:
Shipped at 4℃, Store at -20℃ (Avoid repeated freeze/thaw cycles).
Application:
WB=1:100-500 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 Flow-Cyt=1:20-300 ICC=1:100-500 IF=1:100-500 Anti-RCAS1/EBAG9抗體
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
Not yet tested in other applications.
Optimal working dilutions must be determined by the end user.
